EWTX

SEC source: 0001562180-23-006452 · primarydocument.xml · derivative · entry 1

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-08-17

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-23-006451 · primarydocument.xml · derivative · entry 1

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires 2033-08-17

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-23-005500 · primarydocument.xml · derivative · entry 2

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,122

Underlying: Common Stock · 10,000 shares

Expires 2030-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-23-005500 · primarydocument.xml · nonDerivative · entry 1

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,024

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 2,898 shares purchased on May 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-23-005178 · primarydocument.xml · derivative · entry 1

Fox Jonathan C · CIK 0001655016 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,123

Underlying: Common Stock · 22,123 shares

Expires 2033-06-12

F1 · derivative.exercise_date: 100% of the Stock Options granted on June 12, 2023 will become vested on the earlier of (i) June 12, 2024 or (ii) the business day prior to the date of the 2024 annual meeting of stockholders.

SEC source: 0001562180-23-005177 · primarydocument.xml · derivative · entry 1

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,123

Underlying: Common Stock · 22,123 shares

Expires 2033-06-12

F1 · derivative.exercise_date: 100% of the Stock Options granted on June 12, 2023 will become vested on the earlier of (i) June 12, 2024 or (ii) the business day prior to the date of the 2024 annual meeting of stockholders.

SEC source: 0001562180-23-005176 · primarydocument.xml · derivative · entry 1

ROOT JONATHAN D · CIK 0001225480 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,123

Underlying: Common Stock · 22,123 shares

Expires 2033-06-12

F1 · derivative.exercise_date: 100% of the Stock Options granted on June 12, 2023 will become vested on the earlier of (i) June 12, 2024 or (ii) the business day prior to the date of the 2024 annual meeting of stockholders.

SEC source: 0001562180-23-005175 · primarydocument.xml · derivative · entry 1

Edris Badreddin · CIK 0001786966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,123

Underlying: Common Stock · 22,123 shares

Expires 2033-06-12

F1 · derivative.exercise_date: 100% of the Stock Options granted on June 12, 2023 will become vested on the earlier of (i) June 12, 2024 or (ii) the business day prior to the date of the 2024 annual meeting of stockholders.

SEC source: 0001562180-23-005174 · primarydocument.xml · derivative · entry 1

Brege Laura · CIK 0001365619 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,123

Underlying: Common Stock · 22,123 shares

Expires 2033-06-12

F1 · derivative.exercise_date: 100% of the Stock Options granted on June 12, 2023 will become vested on the earlier of (i) June 12, 2024 or (ii) the business day prior to the date of the 2024 annual meeting of stockholders.

SEC source: 0001562180-23-003920 · primarydocument.xml · nonDerivative · entry 2

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,191

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-23-003923 · primarydocument.xml · nonDerivative · entry 2

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,020

F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-23-003922 · primarydocument.xml · nonDerivative · entry 2

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,565

F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-23-003921 · primarydocument.xml · nonDerivative · entry 2

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,126

F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-23-003919 · primarydocument.xml · nonDerivative · entry 2

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,960

F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-23-003918 · primarydocument.xml · nonDerivative · entry 2

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,213

F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-23-003920 · primarydocument.xml · derivative · entry 3

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,417

Underlying: Common Stock · 5,208 shares

Expires 2032-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001562180-23-003920 · primarydocument.xml · nonDerivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-003923 · primarydocument.xml · derivative · entry 3

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,417

Underlying: Common Stock · 5,208 shares

Expires 2032-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001562180-23-003923 · primarydocument.xml · nonDerivative · entry 1

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,767

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,470 shares purchased on November 15, 2021, 1,239 shares purchased on May 15, 2022 and 850 shares purchased on November 15, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-23-003922 · primarydocument.xml · derivative · entry 3

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,417

Underlying: Common Stock · 5,208 shares

Expires 2032-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001562180-23-003922 · primarydocument.xml · nonDerivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,462

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 254 shares purchased on November 15, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-23-003921 · primarydocument.xml · derivative · entry 3

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,417

Underlying: Common Stock · 5,208 shares

Expires 2032-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001562180-23-003921 · primarydocument.xml · nonDerivative · entry 1

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,462

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 254 shares purchased on November 16, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-23-003919 · primarydocument.xml · derivative · entry 3

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,834

Underlying: Common Stock · 10,416 shares

Expires 2032-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001562180-23-003919 · primarydocument.xml · nonDerivative · entry 1

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,214

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,392 shares purchased on May 15, 2022 and 1,406 shares purchased on November 15, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

SEC source: 0001562180-23-003918 · primarydocument.xml · derivative · entry 7

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,834

Underlying: Common Stock · 10,416 shares

Expires 2032-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: RSUs granted to the Reporting Person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.

SEC source: 0001562180-23-003918 · primarydocument.xml · nonDerivative · entry 1

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,416

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-002584 · primarydocument.xml · derivative · entry 1

Fox Jonathan C · CIK 0001655016 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,731

Underlying: Common Stock · 43,731 shares

Expires 2033-03-03

F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest each month beginning on March 3, 2023, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-23-000045 · primarydocument.xml · derivative · entry 1

Semigran Marc · CIK 0001691494 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2032-12-30

F1 · derivative.exercise_date: 1/4th of the shares subject to the option become vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-007050 · primarydocument.xml · derivative · entry 3

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,997

Underlying: Common Stock · 4,730 shares

Expires 2030-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-007050 · primarydocument.xml · nonDerivative · entry 2

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.47 to $10.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-22-007050 · primarydocument.xml · nonDerivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,730

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000947871-22-000972 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 13,981,952

F1 · price: These shares of the Issuer's common stock ("Shares") were purchased in an underwritten public offering.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI.

F4 · ownership.nature: This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated Peter A. Thompson ("Thompson"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Thompson, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-22-000973 · ownership.xml · nonDerivative · entry 1

Thompson Peter A. · CIK 0001357522 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 13,981,952

F1 · price: These shares of the Issuer's common stock ("Shares") were purchased in an underwritten public offering.

F2 · ownership.nature: The Shares are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. The Reporting Person is a member of OrbiMed Advisors. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI.

F4 · ownership.nature: Each of the Reporting Person, GP VI, OrbiMed Advisors, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, GP VI, OrbiMed Advisors, or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001209191-22-050258 · doc4.xml · nonDerivative · entry 1

Novo Holdings A/S · CIK 0001388325 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,071,703

F1 · price: Represents a purchase from the underwriters in the Issuer's public offering.

SEC source: 0001562180-22-006557 · primarydocument.xml · derivative · entry 4

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,727

Underlying: Common Stock · 4,730 shares

Expires 2030-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly beginning on January 16, 2021, subject to Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-006557 · primarydocument.xml · nonDerivative · entry 3

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.

F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $10.93 to $11.08, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-22-006557 · primarydocument.xml · nonDerivative · entry 2

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,351

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.93 to $10.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-22-006557 · primarydocument.xml · nonDerivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,730

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-22-006029 · primarydocument.xml · derivative · entry 1

Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,000

Underlying: Common Stock · 220,000 shares

Expires 2032-08-08

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 8, 2022, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-006027 · primarydocument.xml · derivative · entry 1

Derakhshan Behrad · CIK 0001853109 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2032-08-08

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 8, 2022, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-006030 · primarydocument.xml · derivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2032-08-08

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 8, 2022, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-006028 · primarydocument.xml · derivative · entry 1

Carruthers R Michael · CIK 0001644467 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2032-08-08

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 8, 2022, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-006026 · primarydocument.xml · derivative · entry 1

Donovan Joanne M. · CIK 0001644087 · CMO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2032-08-08

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 8, 2022, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-006025 · primarydocument.xml · derivative · entry 1

KOCH KEVIN · CIK 0001185829 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550,000

Underlying: Common Stock · 550,000 shares

Expires 2032-08-08

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 8, 2022, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-005918 · primarydocument.xml · derivative · entry 5

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,558

Underlying: Common Stock · 4,502 shares

Expires 2030-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-005918 · primarydocument.xml · derivative · entry 4

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,457

Underlying: Common Stock · 4,730 shares

Expires 2030-12-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date.

SEC source: 0001562180-22-005918 · primarydocument.xml · nonDerivative · entry 3

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $9.07 to $9.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-22-005918 · primarydocument.xml · nonDerivative · entry 2

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,232

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-22-005918 · primarydocument.xml · nonDerivative · entry 1

MOORE JOHN R · CIK 0001191702 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,730

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.